Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide

• Ngā kaituhi matua: Giorgia Urbinati (Author), Isabelle de Waziers (Author), Mateja Slamiç (Author), Tobias Foussignière (Author), Hafiz M Ali (Author), Didier Desmaële (Author), Patrick Couvreur (Author), Liliane Massaad-Massade (Author)
• Hōputu: Pukapuka
• I whakaputaina: Elsevier, 2016-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Our purpose was to develop a new pharmacological approach for the treatment of prostate cancer (PCa), the most common neoplasia in men. Recently, we developed siRNA against the fusion oncogene TMPRSS2-ERG found in 50% of patients and showed an antitumoral activity in animal model. Herein, we want to...